Hepatitis B virus genotyping among chronic hepatitis B patients with resistance to treatment with lamivudine in the City of Ribeirão Preto, State of São Paulo;Genotipagem do vírus da hepatite B de pacientes crônicos com resistência ao tratamento com lamivudina na Cidade de Ribeirão Preto, Estado de São Paulo

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 43, Issue 3, 2010, Pages 224-228

  Haddad, Rodrigo ^a   Martinelli, Ana de Lourdes Candolo ^b   Uyemura, Sérgio Akira ^b   Yokosawa, Jonny ^b  

^a Regional Blood Center of Ribeirão Preto   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

HBV genotype; Hepatitis B; Lamivudine; YMDD

Indexed keywords

LAMIVUDINE; VIRUS DNA;

AMINO ACID SUBSTITUTION; ARTICLE; BRAZIL; CONTROLLED STUDY; DNA SEQUENCE; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; POLYMERASE CHAIN REACTION; PROTEIN MOTIF; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; TREATMENT DURATION;

HEPATITIS B VIRUS;

EID: 77954825079     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0037-86822010000300002     Document Type: Article

References (43)

1. Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003; 23:39-46.
2. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic Hepatitis B virus infection. Antiviral Res 2004; 64:1-5.
3. Lacey L. Review of economic benefits of treating chronic hepatitis B with lamivudine. J Gastroenterol Hepatol 2004; 19:S10-12.
4. Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature 1985; 317:489-495.
5. Mutimer D. Hepatitis B virus infection: resistance to antiviral agents. J Clin Virol 2001; 21:239-242.
6. Wright TL. Clinical Trial Results and Treatment Resistance with lamivudine in hepatitis B. Semin Liver Dis 2004; 24:31-36.
7. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatol 2001; 34:1225-1241.
8. Papatheodoridis GV, Dimou E, Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am J Gastroenterol 2002; 97:1618-1628.
9. Perrilo RP. Overview of treatment of hepatitis B; Key approaches and clinical challenges. Semin Liver Dis 2004; 24:23-29.
10. Fischer KP, Gutfreund KS, Tyrrell DL. Lamivudine resistance in hepatitis B: mechanisms and clinical implications. Drug Resist Updat 2001; 4:118-128.
11. Akuta N, Suzuki F, Kobayashi M, Tsubota A, Suziki Y, Hosaka T, et al. The influence of hepatitis B genotype on the development of lamivudine resistance during long-term treatment. J Hepatol 2003; 38:315-321.
12. Suzuki F, Tsubota A, Arase Y, Suzuki Y, Akuta N, Hosaka T, et al. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis b virus infection in Japan. Intervirol 2003; 46:182-189.
13. Zöllner B, Petersen J, Puchhammer-Stöckl E, Kletzmayr J, Sterneck M, Fischer L, et al. Viral Features of Lamivudine Resistant Hepatitis B Genotypes A and D. Hepatology 2004; 36:42-50.
14. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrel DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatol 1998; 27:1670-1677.
15. Okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo R, Imai M, Miyakawa Y, et al. Typing hepatitis b virus by homology in nucleotide sequence. J Gen Virol 1988; 69:2575-2583.
16. Norder H, Hammas B, Löfdahl S, Couroucé AM, Magnius LO. Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains. J Gen Virol 1992; 73:1201-1208.
17. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, Rossau R. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000; 81:67-74.
18. Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002; 83:2059-2073.
19. Ribeiro NR, Campos GS, Angelo AL, Braga EL, Santana N, Gomes MM, et al. Distribution of hepatitis B virus genotype among patients with chronic infection. Liver Int 2006; 26:636-642.
20. Araujo MN, Melo FCA, Yoshida CFT, Niel C, Gomes SA. High proportion of subgroup A' (genotype A) among Brasilian isolates of Hepatitis B virus. Arch Virol 2004; 149:1383-1395.
21. Niel C, Moraes MTB, Gaspar AMC, Yoshida CFT, Gomes AS. Genetic diversity of hepatitis b virus strains isolated in Rio de Janeiro, Brazil. J Med Virol 1994; 44:180-186.
22. Moraes MTB, Gomes SA, Niel C. Sequence analysis of pre S/S gene of hepatitis B virus strains of genotype A, D and F isolated in Brazil. Arch Virol 1996; 141:1767-1773.
23. Bottecchia M, Souto FJ, O KM, Amendola M, Brandão CE, Niel C, et al. Hepatitis B virus genotypes and resistance mutations in patients under long term lamivudine therapy: characterization of genotype G in Brazil. BMC Microbiol 2008; 8:11.
24. Oliveira CM, Farias IP, Ferraz da Fonseca JC, Brasil LM, de Souza R, et al. Phylogeny and molecular genetic parameters of different stages of hepatitis B virus infection in patients from the Brazilian Amazon. Arch Virol 2008; 153:823-830.
25. Ahmed SNS, Tavan D, Pichoud C, Berby F, Stuyver L, Johnson M, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by Lamivudine for chronic hepatitis B. Hepatol 2000; 32:1078-1088.
26. Felsenstein J. PHYLIP (Phylogeny Inference Package). Distributed by the author. Department of Genetics, The University of Washington, Seattle, WA; 1993; v. 3.5c.
27. Domingo E, Holland JJ. RNA virus mutations and fitness for survival. Annu Rev Microbiol 1997; 51:151-178.
28. Torresi J. The Virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 2002; 25:97-106.
29. Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis 2004; 24:S3-10.
30. Farci P, Shimoda A, Wong D, Cabezon T, De Giovannis D, Strazzera A, et al. Prevention of hepatitis C virus infection in chimpanzees by hyper-immune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 1996; 93:15394-15399.
31. Kirishima T, Okanoue T, Daimon Y, Itoh Y, Nakamura H, Morita A, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol 2002; 37:259-265.
32. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336:325-329.
33. Chen WN, Oon CJ. Hepatitis B virus mutants: An overview. J Gastroenterol Hepatol 2002; 17:497-499.
34. Lok AS, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatol 2000; 32:1172-1174.
35. Ono-Nita SK, Kato N, Shiratori Y, Lan KH, Yoshida H, Carrilho FJ, et al. susceptibility of lamivudine-resistant hepatitis B virus to the other reverse transcriptase inhibitors. J Clin Invest 1999; 103:1635-1640.
36. Melegari M, Scaglioni PP, Wands JR. Hepatitis b virus mutants associated with 3TC and fanciclovir administration are replication defective. Hepatol 1998; 27:628-633.
37. Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ, et al. ymddmotif in hepatitis b virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatol 1999; 29:939-945.
38. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long therapy and re-takeover by wild-type after cessation of therapy. Hepatol 1998; 27:1711-1716.
39. Rezende RE, Fonseca BA, Ramalho LN, Zucoloto S, Pinho JR, Bertolini DA, et al. The precore mutation is associated with severity of liver damage in Brazilian patients with chronic hepatitis B. J Clin Virol 2005; 32:53-59.
40. Kao JH. Clinical relevance of hepatitis B genotypes: A case of déjà vu? J Gastroenterol Hepatol 2002; 17:113-115.
41. Pan XP, Li LJ, Du WB, Li MW, Cao HC, Sheng JF. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine resistant hepatitis B genotypes B and C. J Viral Hepat 2007; 14:767-74.
42. Kobayashi M, Suzuki F, Akuta N, Suzuki Y, Arase Y, Ikeda K, et al. Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C. J Med Virol 2006; 78:1276-1283.
43. Orito E, Fujiwara K, Tanaka Y, Yuen MF, Lai CL, Kato T, et al. A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. Hepatol Res 2006; 35:127-134.